Clinical study of enema aplication of Yiyi-Fuzi-Baijiang powder combined with oral sulfasalazine in treating ulcerative colitis

Objective Evaluation of enema application of Yiyi-Fuzi-Baijiang powder combined with oral sulfasalazine enteric-coated tablets in treating ulcerative colitis. Methods The patients with ulcerative colitis were randomly divided into 2 groups, 42 cases in each group. The control group was treated with sulfasalazine, and the observation group with sulfasalazine and Yiyi-Fuzi-Baijiang powder. Both groups were treated for 4 weeks. ELISA method was used to detect the levels of IL-6, IL-8 and TNF-. The changes of disease activity index (Sutherland DAI) were observed before and after treatment, and the clinical efficacy was evaluated. Results After treatment, the Sutherland DAI (3.89 ± 0.91 vs. 4.91 ± 1.08, t=3.082) in the observation group was significantly lower than that in the control group (P=0.042). The level of TNF- (20.82 ± 4.31 ng/L vs. 26.51 ± 5.25 ng/L, t=3.602), IL-6 (31.73 ± 4.82 ng/L vs. 40.18 ± 5.63 ng/L, t=3.817), and IL-8 (35.39 ± 4.62 ng/L vs. 40.59 ± 5.35 ng/L, t=3.341) in the observation group were significantly lower than those in the control group (P<0.05). The total efficiency of observation group was 92.9% (39/42), and the control group was 73.8% (31/42). There was significant difference between the two groups (χ2=4.200, P=0.040). Conclusions The Yiyi-Fuzi-Baijiang powder combined with sulfasalazine could relieve the clinical symptoms of ulcerative colitis patients with spleen-kidney yang deficiency, and inhibition inflammatory response. Key words: Colitis, ulcerative; Yiyi-Fuzi-Baijiang powder; Retention enema; Interleukin-6; Interleukin-8; Tumor necrosis factor-alpha